• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Earnings Beat, Higher Dividend And New CFO Might Change The Case For Investing In Regis (ASX:REG)

    Simply Wall St·08/26/2026 17:31:32
    语音播报
    • Regis Healthcare Limited (ASX:REG) recently reported full-year 2026 results showing revenue of A$1.54 billion and net income of A$55.69 million, announced a fully franked final dividend of A$0.094 per share, outlined an acquisition-focused growth agenda, and confirmed a CFO transition to Stuart Hooper.
    • The combination of earnings growth, a higher dividend and an active M&A pipeline, supported by a new CFO with deep healthcare experience, signals management’s focus on scaling the business while maintaining financial discipline.
    • We’ll now examine how Regis’s earnings growth and increased dividend influence its existing investment narrative and future growth assumptions.

    The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Regis Healthcare Investment Narrative Recap

    To own Regis Healthcare, you need to believe that long term demand for aged care and ongoing sector reforms can support sustainable earnings and dividends, despite tight funding settings and rising staff costs. The FY2026 result and higher fully franked dividend support the near term earnings and cash generation story, while the most immediate risk remains cost inflation and funding indexation that may not fully cover mandated care minutes and workforce pressures. Overall, this news does not fundamentally alter the short term catalyst or the biggest risk.

    The FY2026 dividend increase to A$0.094 per share stands out in the latest announcements, because it directly connects earnings outcomes with shareholder returns. For investors watching near term catalysts, a higher dividend signals that management is comfortable returning more cash while also pursuing an active acquisition pipeline, even as sector wide wage, care minute and policy risks continue to sit in the background.

    Yet alongside this higher dividend, investors should be aware that rising wage costs and mandated care minutes could still...

    Read the full narrative on Regis Healthcare (it's free!)

    Regis Healthcare's narrative projects A$1.7 billion revenue and A$88.7 million earnings by 2029. This requires 10.2% yearly revenue growth and an A$50.7 million earnings increase from A$38.0 million today.

    Uncover how Regis Healthcare's forecasts yield a A$7.79 fair value, a 27% upside to its current price.

    Exploring Other Perspectives

    ASX:REG 1-Year Stock Price Chart
    ASX:REG 1-Year Stock Price Chart

    Three Simply Wall St Community fair value estimates for Regis range from A$7.26 to A$15.61, underlining how far apart individual views can be. When you set that against the current focus on acquisitions and sector funding risks, it becomes clear why checking several independent opinions on Regis’s earnings resilience and growth assumptions matters.

    Explore 3 other fair value estimates on Regis Healthcare - why the stock might be worth just A$7.26!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For Alternative Opportunities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.